Collegium Pharmaceutical (NASDAQ:COLL) Earns Outperform Rating from Analysts at Leerink Partners

Key Points

• Leerink Partners initiated coverage of Collegium Pharmaceutical with an “outperform” rating and a $45 price target, implying approximately 92.6% upside from the stock’s $23.37 opening price.
• Analyst sentiment is broadly positive but mixed, with the company carrying a “Moderate Buy” consensus rating and an average price target of $48.50.
• Collegium exceeded quarterly earnings expectations, reporting $1.92 EPS versus the $1.72 consensus and $199.88 million in revenue, up 6.3% year over year.

Research analysts at Leerink Partners assumed coverage on shares of Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) in a research report issued to clients and investors on Wednesday, Briefing.com reports. The brokerage set an "outperform" rating and a $45.00 price target on the specialty pharmaceutical company's stock. Leerink Partners' price objective would suggest a potential upside of 92.55% from the stock's current price.

A number of other brokerages have also issued reports on COLL. Needham & Company LLC dropped their price objective on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a "buy" rating for the company in a report on Thursday, August 6th. Wall Street Zen cut shares of Collegium Pharmaceutical from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Truist Financial raised shares of Collegium Pharmaceutical to a "strong-buy" rating in a research note on Monday, June 15th. Weiss Ratings lowered shares of Collegium Pharmaceutical from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday. Finally, Piper Sandler reissued a "neutral" rating and issued a $43.00 price objective (down from $45.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $48.50.

Collegium Pharmaceutical Stock Down 0.7%

Shares of NASDAQ:COLL opened at $23.37 on Wednesday. The company has a debt-to-equity ratio of 3.32, a quick ratio of 0.84 and a current ratio of 1.03. Collegium Pharmaceutical has a 52-week low of $23.11 and a 52-week high of $50.79. The company has a market capitalization of $760.93 million, a PE ratio of 18.85 and a beta of 0.72. The company has a fifty day moving average of $31.35 and a 200-day moving average of $33.90.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, topping analysts' consensus estimates of $1.72 by $0.20. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The business had revenue of $199.88 million for the quarter, compared to analyst estimates of $199.62 million. During the same quarter in the previous year, the company posted $1.68 EPS. Collegium Pharmaceutical's quarterly revenue was up 6.3% compared to the same quarter last year. On average, equities analysts predict that Collegium Pharmaceutical will post 6.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Collegium Pharmaceutical during the second quarter worth $196,972,000. Rubric Capital Management LP lifted its holdings in Collegium Pharmaceutical by 5.3% in the second quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company's stock valued at $93,374,000 after buying an additional 157,743 shares during the period. Vanguard Group Inc. boosted its position in Collegium Pharmaceutical by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company's stock valued at $104,465,000 after acquiring an additional 29,876 shares during the last quarter. Jupiter Topco LLC bought a new stake in Collegium Pharmaceutical during the second quarter valued at $77,743,000. Finally, Janus Henderson Group PLC grew its holdings in Collegium Pharmaceutical by 26.0% during the 1st quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company's stock worth $60,358,000 after acquiring an additional 377,073 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company's core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company's principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.